LOGIN  |  REGISTER
Amneal Pharmaceuticals

Zynex to Present at the H.C. Wainwright Global Investment Conference

September 05, 2023 | Last Trade: US$2.27 0.03 -1.30

ENGLEWOOD, Colo., Sept. 5, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming H.C. Wainwright Global Investment Conference, which is being held on September 11th-13th, 2023.

Zynex's presentation will be held in person and webcast live on September 12th at 3:00 PM ET at the Lotte New York Palace Hotel in New York, NY. You can listen to the webcast at Zynex Investor Presentation Webcast. Dan Moorhead, CFO, will be available for one-on-one meetings on the 12th and 13th.

To receive additional information, register to attend, or schedule a one-on-one meeting, email the H.C. Wainwright team at This email address is being protected from spambots. You need JavaScript enabled to view it..

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page